Profile

Cover photo
117 followers|13,083 views
AboutPostsPhotosVideos

Stream

BioTime

Shared publicly  - 
 
BioTime Announces Issuance of 31 New Patents to Strengthen its Patent Portfolio in Regenerative Medicine

> New Patents Supplement Existing Portfolio of More Than 700 Patents and Patent Applications Owned or Licensed by BioTime Family of Companies Worldwide
BioTime Announces Issuance of 31 New Patents to Strengthen its Patent Portfolio in Regenerative Medicine. New Patents Supplement Existing Portfolio of More Than 700 Patents and Patent Applications Owned or Licensed by BioTime Family of Companies Worldwide. ALAMEDA, Calif. --(BUSINESS WIRE)--Aug.
1
Add a comment...

BioTime

Shared publicly  - 
 
Congratulations to Kite Pharma on this deal with UCLA: a strong validation of the usefulness of Pluripotent Stem Cells.
#stemcells #iPS #regenmed  
Platform for Renewable T-Cell Source Designed to Overcome Limitations of Current Allogeneic Approaches SANTA MONICA, Calif.--(BUSINESS WIRE)-- ...
1
Add a comment...

BioTime

Shared publicly  - 
 
Part 1 of a 2-part segment on FOX2 KTVU (San Francisco) on San Ramon Valley High School graduate Jake Javier, readjusting to life after a diving accident left him paralyzed from the chest down. The second part will focus on the clinical trial from BioTime subsidiary Asterias Biotherapeutics, in which Jake is taking part.

#stemcell #regenmed  
San Ramon Valley High School graduate Jake Javier is relearning how to move after suffering a diving accident in May that left him paralyzed and facing the prospect of never being able to walk again.
1
Add a comment...

BioTime

Shared publicly  - 
 
BioTime Announces $2.2 Million Grant for Further Development of Dry-AMD Program

- Israel Innovation Authority awards a grant to Cell Cure Neurosciences, a BioTime Subsidiary, that will support ongoing development of OpRegen®, to address a leading cause of blindness, dry-AMD

- This is the 10th year in receipt of an Israeli Government grant in support of Cell Cure

$BTX #maculardegeneration #stemcells http://bit.ly/1rgwPtU

1
Add a comment...

BioTime

Shared publicly  - 
 
BioTime subsidiary OncoCyte Presents Positive Bladder Cancer Diagnostic Data at the 2016 American Society of Clinical Oncology Annual Meeting
1
Add a comment...

BioTime

Shared publicly  - 
 
BioTime subsidiary Asterias Biotherapeutics Announces Positive New Long-Term Follow-Up Results for AST-OPC1

-Data Included in Newly Submitted Patent Application for AST-OPC1- - Phase 1 clinical trial assessing the safety of AST-OPC1 (oligodendrocyte progenitor cells) in patients with spinal cord injury 
1
Add a comment...

BioTime

Shared publicly  - 
 
BioTime to report Second Quarter Results on Tuesday, August 9, 2016. $BTX
1
Add a comment...

BioTime

Shared publicly  - 
 
Part 2 of KTVY Fox 2 TV News segment covers the stem cell-based clinical trial for spinal cord injury from Asterias Biotherapeutics in some depth. 
A cutting edge, experimental approach to treat paralyzed victims with stem cells could hold new hope for San Ramon Valley High School football player Jake Javier, who suffered a devastating injury during a backyard diving accident.
1
Add a comment...

BioTime

Shared publicly  - 
 
Asterias Biotherapeutics Completes Enrollment and Dosing for the First Efficacy Cohort of the AST-OPC1 SCiSTAR Phase 1/2a Clinical Trial in Complete Cervical Spinal Cord Injury

- Expects to Announce Six-Month Results From This First Efficacy Cohort in January 2017-

#regenmed #stemcell #spinalcordinjury  
Asterias Biotherapeutics Completes Enrollment and Dosing for the First Efficacy Cohort of the AST-OPC1 SCiSTAR Phase 1/2a Clinical Trial in Complete Cervical Spinal Cord Injury. - Expects to Announce Six-Month Results From This First Efficacy Cohort in January 2017- ...
1
Add a comment...

BioTime

Shared publicly  - 
 
BioTime’s Subsidiary Cell Cure Neurosciences Receives DSMB Approval to Start Second Patient Cohort in Clinical Trial for Dry-AMD

- Safety Confirmed with No Concerns Reported in Cohort 1 - - Approval to Immediately Proceed to Cohort 2 -
1
Add a comment...

BioTime

Shared publicly  - 
 
CIRM reports on "More Good News" from BioTime subsidiary Asterias Biotherapeutics' clinical trial for spinal cord injury.

#CIRM #stemcells #regenmed
$BTX $AST
It’s been less than a year since we last reported on the CIRM-funded Asterias Biotherapeutics trial for spinal cord injury (SCI), and we already have more – still preliminary – but good news to sha…
1
Add a comment...

BioTime

Shared publicly  - 
 
BioTime to Present at Two Upcoming Investor Conferences
1
Add a comment...
Story
Tagline
Developing stem cell-based therapies and products in the area of regenerative medicine
Introduction
BioTime, a biotechnology company headquartered in the San Francisco Bay Area, is focused on biomedical research and product development in regenerative medicine.
Contact Information
Contact info
Phone
(510) 521-3390